Curis, Inc.
CRISHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. With a market capitalization of $3.3M, it sits in micro-cap territory. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Market Cap
$3.3M
Beta
3.00
P/E (TTM)
0.37
P/E (Fwd)
-0.22
EPS (TTM)
$3.65
EPS (Fwd)
$-6.01
ROE
—
ROA
-93.2%
Cash
$5.1M
Total Debt
$1.0M
Free CF
-$15.8M
52W Change
-96.3%
Annual Financials
Cash vs Debt
Where CRIS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CRIS finished 87.11% below its 150-day moving average ($10.71) and 89.77% below its 200-day moving average ($13.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRIS overbought or oversold?
At the September 3, 2026 close, CRIS's RSI(14) was 5.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.1M in cash comfortably exceeding the $1.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$15.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $10.2M (2022) to $9.4M (2025).
Curis, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CRIS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CRIS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.